

Ministry of Health  
and Long-Term Care

Ontario Public Drug Programs

Office of the Executive Officer and  
Assistant Deputy Minister

Hepburn Block, 9<sup>th</sup> Floor  
80 Grosvenor Street  
Queen's Park  
Toronto ON M7A 1R3  
Tel 416-327-0902  
Fax 416-327-5219

Ministère de la Santé  
et des Soins de longue durée

Programmes publics de médicaments  
de l'Ontario

Bureau de l'administratrice en chef et  
sous-ministre adjointe

Édifice Hepburn, 9<sup>e</sup> étage  
80, rue Grosvenor  
Queen's Park  
Toronto ON M7A 1R3  
Tél. : 416 327-0902  
Télééc. : 416 327-5219



13 August 2009

Durhane Wong-Rieger  
President, Canadian Organization for Rare  
Disorders  
151 Bloor Street West, Suite 600  
Toronto ON  
M5S 1S4

Ed Koning  
President, Canadian Fabry Association  
9011-142 St. NW  
Edmonton, Alberta  
T5R 0M6

Dear Durhane; Ed

We acknowledge the work that both the Canadian Organization for Rare Disorders and Canadian Fabry Association have done to raise awareness regarding the funding of Fabrazyme and Replagal for Fabry patients across Canada. We are continuing to work with the provinces to establish funding after September 30, 2009 and to maintain the work that is being done through the Canadian Fabry Disease Initiative.

As you are aware, Ontario is leading the work on behalf of all provinces and territories with respect to renewing and/or revising the agreement. We are working closely with the manufacturers, researchers, provinces and patient community to review the existing agreements and determine what changes, if any, would be required to reflect the future funding commitments. If you have any comments on the current process, please feel free to forward them to my attention.

This work is an extremely high priority for us. I wanted to formally confirm to you Ontario's commitment to funding Fabrazyme and Replagal for Ontario patients beyond September 30, 2009.

Kind regards,

Helen Stevenson  
Assistant Deputy Minister and  
Executive Officer, Ontario Public Drug Programs